- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
P3 data, Journal, Metastases: Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. (Pubmed Central) - Jul 17, 2024
Oral relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation than leuprolide acetate in a subset of men from the HERO study. The clinical implications of a faster testosterone recovery with relugolix may be significant for men being treated with androgen deprivation therapy and influence treatment decisions.
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Clinical, Journal, Metastases: Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. (Pubmed Central) - Mar 7, 2024
This multicenter post hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in 2 randomized clinical trials (a phase 2 trial of relugolix vs degarelix, and a subset of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radiotherapy and short-term (24 weeks) ADT (n?=?103) from 2014 to 2015 and men receiving radiotherapy and longer-term (48 weeks) ADT (n?=?157) from 2017 to 2019...Patients receiving longer-term ADT received relugolix, 120 mg, orally once daily (360-mg loading dose) or leuprolide acetate injections every 12 weeks for 48 weeks, with up to 90 days of follow-up...The results of these 2 randomized clinical trials suggest that relugolix rapidly achieves sustained castration in patients with localized and advanced prostate cancer receiving radiotherapy. No new safety concerns were identified when relugolix was used with radiotherapy.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., leuprolide acetate injection / Generic mfg.
Characterizing the Neural Substrates of Irritability in Women: A 7T fMRI Study (Sapphire AB) - Apr 29, 2023 - Abstract #SOBP2023SOBP_473;
Results After hormone add-back, HS+ (vs. HS-) participants showed increased activation in the pregenual anterior cingulate cortex (k=374) and left putamen (k=143) during rigged feedback relative to positive feedback (TFCE, p<0.05, uncorrected). Conclusions Preliminary analyses suggest HS+ participants show increased activation in regions specific to mood regulation and reward processing during frustration after inducing hormone changes similar to the perinatal period.
|
